Arya Pharma (pty) Ltd. Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: Arya Pharma (pty) Ltd. Pharmaceutical Import Records from India — 2 Products, $2.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Arya Pharma (pty) Ltd. — Pharmaceutical Importer Profile (2026) | 2 Products, $2.9M Trade | TransData Nexus

Arya Pharma (pty) Ltd. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Arya Pharma (Pty) Ltd. is a South African pharmaceutical importer and distributor specializing in the procurement and distribution of generic medicines, allied healthcare products, and medical devices. Established by a group of independent pharmacists in 2018, the company is headquartered at the corner of North Reef and Barbara Road, Germiston, South Africa. Arya Pharma operates as a Level 1 B-BBEE (Broad-Based Black Economic Empowerment) entity, reflecting its commitment to transformation and empowerment within the South African business landscape. (aryapharma.co.za)

The company's mission is to make effective, value-added healthcare accessible to all primary healthcare facilities. Arya Pharma achieves this by partnering with pharmacy groups and retailers through house brand agreements, thereby expanding its reach and impact within the healthcare sector. (aryapharma.co.za)

2Distribution Network

Arya Pharma's distribution network is strategically located to serve the South African market effectively. The company's primary warehouse is situated at the corner of North Reef and Barbara Road, Germiston, South Africa. This central location facilitates efficient logistics and distribution across the country. While specific details about additional warehouse locations or logistics capabilities are not publicly disclosed, Arya Pharma's partnerships with pharmacy groups and retailers suggest a robust distribution framework capable of meeting national demand. (aryapharma.co.za)

3Industry Role

In South Africa's pharmaceutical supply chain, Arya Pharma (Pty) Ltd. functions as a distributor, acting as an agent or representative of manufacturers. The company imports finished pharmaceutical formulations from India and distributes them to various healthcare providers, including pharmacies, hospitals, and clinics. This role is consistent with the definition of a distributor under South African pharmaceutical regulations, where distributors sell medicines on behalf of manufacturers or wholesalers. (hsf.org.za)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Arya Pharma (pty) Ltd.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Arya Pharma's sourcing strategy exhibits a high degree of concentration, importing a limited range of products from a single country. The company has imported a total of 161 shipments from India, with a total import value of $2.9 million USD. The product portfolio comprises two products within the cardiovascular therapeutic category: Enalapril ($2.3 million, 1.0% share) and Atenolol ($630,000, 1.5% share). This concentration indicates a strategic focus on specific high-demand cardiovascular medications.

While such concentration can lead to favorable terms and streamlined operations, it also poses risks related to supply chain disruptions, currency fluctuations, and dependency on a single supplier. The absence of diversification in sourcing may impact the company's ability to adapt to market changes or regulatory shifts in the supplier country.

2Supply Chain Resilience

Arya Pharma's supply chain resilience is closely tied to its sourcing strategy from India. The company's focus on a narrow product range from a single supplier may limit its ability to diversify risk. In the event of supply chain disruptions in India, such as production delays or regulatory changes, Arya Pharma could face challenges in maintaining consistent product availability.

To enhance resilience, Arya Pharma could consider establishing relationships with multiple suppliers or diversifying its product portfolio. Additionally, ensuring that suppliers adhere to recognized Good Manufacturing Practices (GMP) and maintaining compliance with international quality standards would further strengthen the supply chain's robustness.

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

The South African Health Products Regulatory Authority (SAHPRA) is the primary regulatory body overseeing the importation, distribution, and sale of medicines in South Africa. SAHPRA operates under the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), as amended, which provides the legal framework for regulating health products in the country. (sahpra.org.za)

Key legislation governing pharmaceutical imports includes the Medicines and Related Substances Act and the General Regulations. These regulations stipulate that only licensed manufacturers, wholesalers, and distributors may import medicines into South Africa. The Act also outlines the requirements for the registration of medicines, ensuring that imported products meet the necessary quality, safety, and efficacy standards. (hsf.org.za)

2Import Licensing & GMP

To import medicines into South Africa, companies must obtain a license from SAHPRA, authorizing them to import and distribute specific categories of health products. This license ensures that the importer complies with all regulatory requirements and maintains the necessary standards for handling pharmaceutical products. (sahpra.org.za)

Good Manufacturing Practice (GMP) certification is a critical component of the import licensing process. SAHPRA requires that imported medicines be manufactured in facilities that adhere to recognized GMP standards, such as those established by the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This certification ensures that the manufacturing processes meet international quality standards, thereby safeguarding public health.

Arya Pharma (pty) Ltd. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Arya Pharma's focus on cardiovascular medications, specifically Enalapril and Atenolol, aligns with the high prevalence of cardiovascular diseases in South Africa. By importing these essential medicines, Arya Pharma addresses a critical healthcare need, ensuring that effective treatments are accessible to patients. The company's strategic emphasis on these products reflects a commitment to improving public health outcomes in the region.

The demand for cardiovascular medications in South Africa is driven by factors such as an aging population, increasing incidence of hypertension, and lifestyle-related risk factors. By concentrating on this therapeutic area, Arya Pharma positions itself as a key player in the South African pharmaceutical market, catering to a significant and growing patient population.

2Sourcing Profile

Arya Pharma's sourcing strategy is centered on importing finished pharmaceutical formulations from India, a country known for its robust pharmaceutical manufacturing sector. This approach allows Arya Pharma to offer cost-effective and high-quality generic medicines to the South African market.

The company's focus on finished dosage forms, such as tablets and capsules, indicates a preference for ready-to-use products that meet international quality standards. By sourcing from India, Arya Pharma leverages the country's manufacturing capabilities and established regulatory compliance to ensure the reliability and safety of its product offerings.

Seller's Guide — How to Become a Supplier to Arya Pharma (pty) Ltd.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the South African market by partnering with Arya Pharma. Given Arya Pharma's established distribution network and focus on high-quality generic medicines, Indian exporters can leverage this partnership to expand their market presence.

To identify potential gaps in Arya Pharma's current sourcing, Indian suppliers should assess the therapeutic areas and product forms that Arya Pharma imports. By offering complementary products or formulations that align

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Arya Pharma (pty) Ltd.

What products does Arya Pharma (pty) Ltd. import from India?

Arya Pharma (pty) Ltd. imports 2 pharmaceutical products across 1 categories. Top imports: Enalapril ($2.3M), Atenolol ($629.7K).

What is Arya Pharma (pty) Ltd.'s total pharmaceutical import value?

Arya Pharma (pty) Ltd.'s total pharmaceutical import value from India is $2.9M, based on 161 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Arya Pharma (pty) Ltd. focus on?

Arya Pharma (pty) Ltd. imports across 1 categories. The largest: Cardiovascular (100.0%).

Get Full Arya Pharma (pty) Ltd. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Arya Pharma (pty) Ltd.

Arya Pharma (pty) Ltd. — Import Portfolio & Supplier Network

What Products Does Arya Pharma (pty) Ltd. Import?

Top Products by Import Value

Arya Pharma (pty) Ltd. Therapeutic Categories — 1 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Related Trade Data

Need Detailed Data?